Use Redistricting Maps to Make Organ Allocation More Equitable, Johns Hopkins Researchers Advocate
Currently, in the United States, where you live dictates the availability of a liver transplant. Studies show that geography can mean the difference between a 10 percent chance of dying while on the waiting list for a donor liver, and a 90 percent chance, the researchers say. The new model depends not on the longstanding relationships among medical centers used to create the current unbalanced system, but on making the distribution of organs as equitable as possible, they say.
“This is gerrymandering for the public good,” says study leader Dorry L. Segev, M.D., Ph.D., an associate professor of surgery and epidemiology at the Johns Hopkins University School of Medicine. “We have applied to transplantation the same math used for political redistricting, school assignments, wildlife preservation and zoning issues.” A report on the research is published in online in the American Journal of Transplantation.
“Some geographic areas have very good access to donated organs and some have desperate gaps between organ supply and organ demand,” says co-author Sommer Gentry, Ph.D., a research associate in the department of surgery at Johns Hopkins and an associate professor of mathematics at the U.S. Naval Academy. “Our model helps decrease geographic disparity. It’s not fair that where you live so vastly affects your ability to get a transplant. We want to fix that.”
Currently, patients with the most severe disease go to the top of the liver transplant waiting list. But the list isn’t a single national list; instead, it is subdivided according to location. Thus, the sickest person in one region may be much sicker than the person in a nearby region who gets a new liver, simply because the second region has a greater supply — or smaller demand — for organs.
In 2009, the late Apple founder Steve Jobs, who lived in Northern California, famously underwent a liver transplant in Memphis, Tenn. There, he had put himself on one of the shortest waiting lists in the country. In Tennessee in 2006, it took 48 days to receive a liver transplant, compared with 306 days nationally. Jobs was able to do this because he had the financial resources to immediately fly to Tennessee when the liver became available. His situation brought national attention to the large geographic disparities in liver transplantation.
Segev, a transplant surgeon, says that if a patient from San Francisco or New York City needed a liver transplant, it would be difficult to recommend one of the great transplant centers in those cities because the wait is so long.
In developing their new allocation model, the Johns Hopkins researchers essentially redistricted the regions by analyzing supply, demand and access factors for 6,700 deceased donors, 28,063 liver transplant candidates and 242,727 changes in 2010 to what is known as MELD (Model for End-Stage Liver Disease), a score that categorizes the sickest patients on the list at any given time.
The optimal regional sharing map they created would reduce geographic disparity by half, while significantly reducing waitlist deaths.
Segev, the director of clinical research for transplant surgery at Johns Hopkins, says that the geographic disparity in the current allocation system violates government rules that say geography shouldn’t affect organ supply.
He says he hopes the United Network for Organ Sharing, the private, nonprofit organization that manages the nation’s organ transplant system under contract with the federal government, will act on this new model.
Source: Johns Hopkins Medicine
Published on : Fri, 12 Jul 2013
Print as PDF
The HAMILTON-C1 neo is a versatile neonatal ventilator that combines invasive and noninvasive modes with the additional options of nCPAP and high flow oxygen therapy. The integrated turbine allows it to be operated independently of a compressed air supply....
17 critical parameters from a blood sample as small as 45 µL Not available in the US When the sample is small but your diagnostic needs are big, the ABL90 FLEX PLUS blood gas analyzer provides critical insights with a turnaround time of less than...
The HAMILTON-C6 represents a new Generation of high-end ventilators. The combination of modularity, ease of use, mobility, and advanced features allows you to individualize your patient's ventilation therapy: - State-of-the-art ventilation modes for adult,...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...